The United Laboratories International Holdings Limited announced that on 26 September 2023, the investigational new drug application (IND) for UBT251 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly-owned subsidiary of the Company, on indications of adult type 2 diabetes, overweight or obesity, was approved by the U.S. Food and Drug Administration ("FDA") with IND numbers of 167739 and 167740. UBT251 is a triple-targeted GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) receptor agonist independently developed by the Company.

The Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide, and has already obtained approval for clinical trials in both China and the US. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.